PTC Therapeutics (FRA:BH3) 3-Year Revenue Growth Rate : 29.50% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics 3-Year Revenue Growth Rate?

PTC Therapeutics's Revenue per Share for the three months ended in Dec. 2023 was €3.73.

During the past 12 months, PTC Therapeutics's average Revenue per Share Growth Rate was 28.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 29.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 19.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of PTC Therapeutics was 83.70% per year. The lowest was -42.40% per year. And the median was 16.80% per year.

Competitive Comparison of PTC Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, PTC Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's 3-Year Revenue Growth Rate falls into.

PTC Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

PTC Therapeutics (FRA:BH3) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

PTC Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics (FRA:BH3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

PTCT:USA BH3:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics (FRA:BH3) Headlines

No Headlines